Our data suggests that while both BCR and MyD88 signaling in B cells promote IL-35 expression in vitro, BCR signaling plays a dominant role in IL-35 expression in vivo in response to pancreatic cancer. The gene discussed is BCR; the disease is familial pancreatic carcinoma.